Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  selinexor
Find trials that include:  Any drugs shown
Results 1-25 of 25 for your search:
Start Over
Selinexor in Advanced Liposarcoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 12 and over
Trial IDs: KCP-330-020, NCI-2016-00746, NCT02606461
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin Hydrochloride For Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17814, NCI-2014-02019, NCT02186834
Selinexor, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: SELHEM, NCI-2014-01704, NCT02212561
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-017, NCI-2016-01115, NCT02343042
Cladribine, Cytarabine, and Filgrastim in Combination with Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 201505084, NCI-2015-00828, NCT02416908
Selinexor and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0975, NCI-2015-01523, NCT02530476
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-004, NCI-2014-01569, NCT01986348
Selinexor (KPT-330) in Older Patients With Relapsed AML
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: KCP-330-008, NCI-2014-00820, NCT02088541
Selinexor in Treating Patients with Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14552, NCI-2014-01936, NCT02215161
Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-009, NCI-2014-02149, NCT02227251
Selinexor in Treating Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-005, NCI-2014-01914, NCT02228525
Selinexor Treatment of Refractory Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-012, NCI-2015-00666, NCT02336815
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-015, NCI-2016-00172, NCT02628704
Selinexor with Induction, Consolidation, and Maintenance Therapy in Treating Older Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: CCCWFU 22316, NCI-2016-00951, NCT02835222
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Decitabine and Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OSU-13182, NCI-2014-00559, 2014C0005, NCT02093403
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0033, NCI-2014-01199, KPT-CFZ, NCT02199665
Selinexor, Paclitaxel, and Carboplatin in Treating Patients with Advanced Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-110, NCI-2014-02205, NCT02269293
Selinexor and Chemotherapy in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 14089, NCI-2014-02229, NCT02299518
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0640, NCI-2015-00693, NCT02419495
Selinexor in Treating Patients with Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome after Transplant
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB14-1426, NCI-2015-00997, NCT02485535
Selinexor with Combination Chemotherapy in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB15-0412, NCI-2015-01647, NCT02573363
Selinexor, Ixazomib Citrate, and Low Dose Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-310, NCI-2016-01538, NCT02831686
Start Over